Immune Checkpoint Inhibitor Toxicity

December 26, 2018

Written by Vivian Lei

Spoon Feed
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitors of T-cell activation and function. They are increasingly used in different malignancies by removing inhibition of T-cell function. However, this also facilitates autoimmune activity against multiple organs. Autoimmune adverse events are most common during the first 12 weeks of therapy but may occur up to 6 months following treatment discontinuation.

Why does this matter?
More and more cancer patients are taking these agents. This review in JAMA Insights highlights the most common ICI toxicities that a clinician may encounter and what to do about them.

Primary mechanisms of ICIs include:

• Inhibition of cytotoxic T lymphocyte antigen 4 (CTLA-4; i.e., ipilimumab)

• Inhibition of programmed death 1 (PD-1; i.e., novolumab, pembrolizumab)

• Inhibition of programmed death ligand 1 (PD-L1; i.e., atezolizumab, avelumab, durvalumab)

The high gravity beer of chemo drugs – disinhibited, disorderly T-cells
Here is a table of the most common side effects by organ system. High-dose steroid treatment is the main way to shut down the toxic effects.

<div
    class="
      image-block-outer-wrapper
      layout-caption-below
      design-layout-inline
      combination-animation-none
      individual-animation-none
      individual-text-animation-none
    "
    data-test="image-block-inline-outer-wrapper"
>
    <figure
        class="
          sqs-block-image-figure
          intrinsic
        "
        style="max-width:1066px;"
    >
      <div
          class="image-block-wrapper"
          data-animation-role="image"
      >
        <div class="sqs-image-shape-container-element
          has-aspect-ratio
        " style="
            position: relative;
              padding-bottom:125.32832336425781%;

overflow: hidden;
”
>